Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with
inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid
Arthritis.